“…Diabetes can represent by itself or even more intense in combination with other possible chronic diseases (dislipidemia, hypertension) or life style (smoking, alcohol consumption, inactivity) the risk for developing different cardiovascular diseases (Levenson et al, 2002;Atanasijević-Kunc et al, 2008c;. Additional aspect, important for modelling structure, can represent social and economical burden of the discussed disease and/or treatment efficacy, which is often interpreted through different pharmacoeconomical studies (Boutayeb et al, 2004;Tarride et al, 2010;Arnold, 2010;Atanasijević-Kunc et al, 2011), where cost-effectiveness analysis and cost -utility analysis provide a basic comparison of different treatment policies or drug efficacy. All mentioned situations can be interpreted as open or closed -loop problems (Atanasijević- Kunc et al, 2008c;Bellazzi, 2001;Lam, 2002;Makroglou, 2006), where especially in the second case the analysis should take into account stability and sensitivity of system behaviour.…”